68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma :...

Area of Science:

• Nuclear Medicine
• Oncology
• Molecular Imaging

Background:

• Acute myeloid leukemia (AML) poses diagnostic challenges, particularly in detecting widespread infiltration.
• Current imaging modalities like 18F-FDG PET/CT have limitations in visualizing certain aspects of AML.
• CXCR4 receptor expression is implicated in AML pathogenesis and progression.

Purpose of the Study:

• To evaluate the diagnostic performance of 68Ga-CXCR4 PET/CT compared to 18F-FDG PET/CT in a patient with AML.
• To assess the utility of CXCR4-targeted imaging for detecting AML infiltration in lymph nodes, bone marrow, and spleen.
• To explore the potential of 68Ga-CXCR4 PET/CT in identifying high-risk AML.

Main Methods:

• Positron emission tomography/computed tomography (PET/CT) imaging was performed using both 18F-FDG and 68Ga-CXCR4 tracers.
• The study involved a single patient diagnosed with acute myeloid leukemia and granulocytic sarcoma.
• Imaging findings were compared between the two radiotracers to assess differences in detection capabilities.

Main Results:

• 68Ga-CXCR4 PET/CT identified a greater number of malignant lymph nodes compared to 18F-FDG PET/CT.
• More intense radiotracer uptake was observed in lymph nodes, bone marrow, and spleen with 68Ga-CXCR4 compared to 18F-FDG.
• The findings suggest enhanced sensitivity of 68Ga-CXCR4 PET/CT in visualizing AML infiltration.

Conclusions:

• 68Ga-CXCR4 PET/CT demonstrates superior sensitivity in detecting acute myeloid leukemia infiltration compared to 18F-FDG PET/CT.
• CXCR4-targeted imaging holds promise for improved diagnostic accuracy in high-risk AML.
• Further research into CXCR4-targeted imaging and therapies for AML is warranted.